ChemicalBook > CAS DataBase List > Orforglipron

Orforglipron

Product Name
Orforglipron
CAS No.
2212020-52-3
Chemical Name
Orforglipron
Synonyms
LY3502970;OWL 833;Ogerlon;Oglegron;Orforglipron;0rforglipron;Orforglipron（LY3502970）;LY3502970 (Orforglipron);Orforglipron, 10 mM in DMSO;Research Grade Orforglipron
CBNumber
CB45419742
Molecular Formula
C48H48F2N10O5
Formula Weight
882.97
MOL File
2212020-52-3.mol
More
Less

Orforglipron Property

Density 
1.50±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
DMSO : 125 mg/mL (141.57 mM)
form 
Solid
pka
7.33±0.20(Predicted)
color 
Off-white to light yellow
InChIKey
USUWIEBBBWHKNI-BBGRWQLENA-N
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

ChemScene
Product number
CS-0043632
Product name
GLP-1receptoragonist1
Purity
99.42%
Packaging
5mg
Price
$1100
Updated
2021/12/16
ChemScene
Product number
CS-0043632
Product name
GLP-1receptoragonist1
Purity
99.42%
Packaging
10mg
Price
$1800
Updated
2021/12/16
ChemScene
Product number
CS-0043632
Product name
GLP-1receptoragonist1
Purity
99.42%
Packaging
25mg
Price
$3900
Updated
2021/12/16
ChemScene
Product number
CS-0043632
Product name
GLP-1receptoragonist1
Purity
99.42%
Packaging
50mg
Price
$6500
Updated
2021/12/16
ChemScene
Product number
CS-0043632
Product name
GLP-1receptoragonist1
Purity
99.42%
Packaging
100mg
Price
$9950
Updated
2021/12/16
More
Less

Orforglipron Chemical Properties,Usage,Production

Description

Orforglipron (LY3502970) (GLP-1 receptor agonist 1) is  GLP-1 receptor agonist extracted from patent WO2018056453A1, Compound 67.

History

Orforglipron is an oral, non-peptide, small-molecule glucagon-like peptide-1 receptor agonist developed by Eli Lilly and Company as a weight-loss drug. Currently, the drug is still in Phase III clinical trials and has not yet received approval from the U.S. Food and Drug Administration (FDA). Eli Lilly's CEO expects the FDA to approve its investigational oral weight-loss drug, orforglipron, by March 2026, and to submit an application for the treatment of type 2 diabetes by the end of 2026.

Uses

Orforglipron is a non-peptide oral glucagon-like peptide-1 receptor agonist (GLP-1RA) widely used in the management of type 2 diabetes mellitus (T2DM) and obesity. In T2DM patients, the drug reduces glycated haemoglobin (HbA1c) by up to 2.10%, facilitates weight loss of up to 10.1 kilograms, and reduces waist circumference by up to 8.7 centimetres. Studies in overweight or obese populations indicate weight loss of up to 13.0 kilograms. Adverse reactions include mild to moderate vomiting and nausea, particularly common following high-dose therapy or rapid dose escalation. Consequently, it should be used cautiously under medical supervision.

Uses

Glucagon-like peptide-1 (GLP-1) agonists (also known as GLP-1 receptor agonists, incretin mimetics, or GLP-1 analogs) represent a class of medications used to treat type 2 diabetes mellitus and, in some cases, obesity.

in vivo

Orforglipron (0.94-4.8 nM in plasma concentration, i.v., or 0.05-0.1 mg/mL, i.g. for 5 days) suppresses food intake in a dose-dependent manner, promotes insulin secretion and decreases blood glucose in cynomolgus monkey model[1].
Orforglipron (0.05-1.35 mg/kg, i.g.) reaches Cmax 2 hours after administration at all doses, exhibits proportional ratio of increase in plasma drug exposure to dose increase, indicates a dose-dependent absorption in the gastrointestinal tract[1].

Pharmacokinetic Analysis of Orforglipron in cynomolgus monkey [1]

routeDose (mg/kg)Tmax (h)Cmax (ng/mL)AUC0-24h (ng·h/mL)
i.g.0.052.04.7823.7
i.g.0.152.020.7135
i.g.0.452.032.0208
i.g.1.352.01481040
Animal Model:cynomolgus monkey model[1]
Dosage:0.9-4.8 nM; 0.05-0.1 mg/mL
Administration:continuous i.v. administration for 30 minutes until a plasma concentration of 0.9-4.8 nM at steady state;
i.g. for 5 days with dose of 0.05-0.1 mg/mL
Result:Increased insulin secretion and decreased plasma-glucose. Suppressed food intake in a dose-dependent manner.

Orforglipron Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Orforglipron Suppliers

China 231 United States 6 Global 237
Hangzhou Go Top Peptide Biotech
Tel
15397062932
Email
sales1@gotopbio.com
Country
China
ProdList
2982
Advantage
58
Chengdu Yunyidian Biological Technology Co.,Ltd
Tel
17621298782
Email
sales@cdyunyidian.com
Country
China
ProdList
258
Advantage
58
Chengdu DingDang Pharmaceutical Co., Ltd.
Tel
028-86040038 13980902949;
Fax
028-85149890
Email
market@dingdangchem.com
Country
China
ProdList
1854
Advantage
55
Zhejiang Brunova Technology Co., Ltd.
Tel
13735468882 17857108485
Email
info@zjbrunova.com
Country
China
ProdList
95
Advantage
58
Chunchuang (Wuhan) Technology Co., Ltd
Tel
15727060112
Email
yutianchun2007@126.com
Country
China
ProdList
9858
Advantage
58
Nantong Nuotai Biomedical Technology Co., Ltd.
Tel
0513-82206272 17706270880
Email
2057095228@qq.com
Country
China
ProdList
204
Advantage
58
Nanjing Lebang Pharmaceutical Technology Co., Ltd
Tel
18860950986
Email
tangmanman@lebangpharma.com
Country
China
ProdList
739
Advantage
58
Taizhou Yuxin Biotechnology Co., Ltd.,
Tel
+86-0576--88902229 +86-13968687450
Email
yuxin@yuxchem.com
Country
China
ProdList
262
Advantage
58
Hiray Pharma Solutions Ltd.
Tel
13618667608
Fax
0724-6815660
Email
maggie_q@hiraypharma.com
Country
China
ProdList
48
Advantage
58
Chembest Research Laboratories Limited
Tel
021-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6003
Advantage
61
More
Less

View Lastest Price from Orforglipron manufacturers

Jinan Hong Kongda Chemical Co.,LTD
Product
Orforglipron 2212020-52-3
Price
US $0.00/kg
Min. Order
1kg
Purity
99.0%
Supply Ability
1000kg
Release date
2026-03-20
Shanghai Joy Biotech Ltd.
Product
Orforglipron 2212020-52-3
Price
US $0.00-0.00/g
Min. Order
1g
Purity
99%
Supply Ability
1000kg
Release date
2026-03-12
Rongchuang International
Product
Orforglipron 2212020-52-3
Price
US $150.00/g
Min. Order
1g
Purity
99.9
Supply Ability
9999
Release date
2026-03-03

2212020-52-3, OrforglipronRelated Search:

(S,E)-1-(4-fluoro-1-methyl-1H-indazol-5-yl)-3-(2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-1-(2-hydroxyvinyl)urea \\ 5-[(S)-2,2-Dimethyltetrahydro-2H-pyran-4-yl]-1-[(1S,2S)-2-methyl-1-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)cyclopropyl]-1H-indole-2-carboxylic Acid 1H-Indole-2-carboxamide, N-methyl-N-phenyl-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]- (R)-1-(4-fluoro-1-methyl-1H-indazol-5-yl)-3-(2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-1,3-dihydro-2H-imidazol-2-one 3-((1S,2R)-1-(5-((R)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((R)-3- (3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1Himidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7- tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2- methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one Ly3502970

  • 1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcy...
  • GLP-1 receptor agonist 1 USP/EP/BP
  • Orforglipron
  • Orforglipron（LY3502970）
  • LY3502970 (Orforglipron)
  • 3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one
  • OWL 833
  • LY3502970|||GLP-1 receptor agonist 1
  • 3-((1S,2S)-1-(5-((S)-2,2-Dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl
  • 1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcyclopropyl]-
  • Orforglipron, 10 mM in DMSO
  • Research Grade Orforglipron
  • 1,2,4-Oxadiazol-5(2H)-one,3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazChemicalbookol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcy
  • 1,2,4-Oxadiazol-5(2H)-one,3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazChemicalbookol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H
  • 0rforglipron
  • 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcyclopropyl]-1,2,4-Oxadiazol-5(2H)-one
  • Ogerlon
  • Orforglipron，PhEur/USP(DMF)
  • Orforglipron raw materials,Peptide customization
  • Orforglipron/GLP-1 receptor agonist 1
  • 3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahyd
  • 3-[(1S,2S)-1-[5-[(4S)-2,2-Dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-1,2,4-oxadiazolidin-5-one
  • 3-((1S,2S)-1-(5-((R)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-...
  • 3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-imidazole-5-yl)-2-oxy-2,3-dihydro-1H-imidazole-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyridineazolebenzo[4,3-c]pyridine-5-carbonyl)-1H-indole-1-yl)-2-methylcyclopropyl-4,5,6,7-diazole-5(4H)-one
  • LY3502970
  • Oglegron
  • 2212020-52-3
  • C48H48F2N10O5
  • 1
  • ADVANCED INT.
  • API